Trials / Completed
CompletedNCT01022996
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
An Open-label, Single-arm Phase II Study of RAD001 in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess RAD001 in patients with refractory or relapsed Hodgkin Lymphoma that has progressed after high-dose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine- or vinorelbine- or vinblastine-based treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus (RAD001) | Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters. |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2009-12-01
- Last updated
- 2016-05-18
- Results posted
- 2016-04-06
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01022996. Inclusion in this directory is not an endorsement.